Aligos Therapeutics, Inc. Stock Price, News & Analysis

Aligos Therapeutics (Nasdaq: ALGS) presented preliminary Phase 1 data from its chronic hepatitis B (CHB) and nonalcoholic steatohepatitis (NASH) programs at the 2022 European Association for the Study of the Liver Congress. Highlights include significant reductions in HBV DNA and RNA in CHB patients after 28 days of treatment with ALG-000184. Additionally, preliminary results for ALG-055009 in hyperlipidemia patients showed favorable pharmacokinetics and safety. Aligos aims for broader clinical trials and further data releases in Q3 2022.

Aligos Therapeutics announced its participation in the Metropolitan AntiViral Drug Accelerator (MAVDA), a consortium recently awarded a $65 million grant from the NIH and NIAID. MAVDA aims to develop novel antiviral treatments for SARS-CoV-2 and other pandemic viruses. Aligos plans to advance its 3CLpro inhibitor, ALG-097558, into clinical trials, which has shown superior potency against COVID-19 variants compared to existing treatments. The collaboration includes experts from top universities and pharmaceutical companies to expedite drug development.

Aligos Therapeutics (Nasdaq: ALGS) announced that its Chairman and CEO, Lawrence M. Blatt, Ph.D., MBA, will present at the Jefferies Healthcare Conference on June 8, 2022, at 3:30 PM ET in New York City. The session will cover the company's efforts in developing therapies for viral and liver diseases.

Additionally, Aligos management will participate in investor 1x1 meetings during the conference. A replay of the presentation will be available for 90 days on Aligos' investor website.

Aligos Therapeutics (Nasdaq: ALGS) reported its Q1 2022 financial results, highlighting a net loss of $35.6 million, compared to $27.7 million in Q1 2021. Cash reserves totaled $183.2 million as of March 31, 2022, down from $205.8 million at the end of 2021, but sufficient to fund operations until mid-2024. Despite terminating its STOPS™ and ASO HBV programs due to poor results, Aligos is advancing its pipeline with multiple candidates, including ALG-000184 for HBV and ALG-097558, a coronavirus inhibitor, expected to file for clinical trials in H2 2022.

Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced the presentation of three posters on its chronic hepatitis B (CHB) portfolio at the International Liver Congress 2022 in London from June 22-26, 2022. The posters will cover the safety and efficacy of the class II capsid assembly modulator ALG-000184, the HBV siRNA ALG-125755, and oral PDL1 inhibitors for CHB treatment. These presentations aim to advance Aligos’ diverse CHB portfolio, potentially improving outcomes for patients. The company is committed to developing targeted therapies for viral infections and liver diseases.

Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced plans to report its first quarter 2022 financial results on May 4, 2022, after U.S. market close. The company focuses on developing innovative therapeutics for viral and liver diseases, including chronic hepatitis B and nonalcoholic steatohepatitis (NASH). Established in 2018, Aligos aims to leverage its expertise in drug development to advance its therapeutic pipeline.

Forward-looking statements in the release highlight potential risks in drug development and market conditions.

Aligos Therapeutics (Nasdaq: ALGS) has announced the selection of ALG-097558 as its leading candidate for development as an antiviral therapeutic against SARS-CoV-2. The compound exhibits potent antiviral activity, being 9 to 20 times more effective than nirmatrelvir against various SARS-CoV-2 variants. Aligos plans to submit a Phase 1 clinical trial application in the second half of 2022 as part of its collaboration with KU Leuven. This development underscores the ongoing need for effective treatments as COVID-19 continues to pose a global health challenge.

Aligos Therapeutics (Nasdaq: ALGS) has discontinued the development of its drug candidate, ALG-020572, for chronic hepatitis B (CHB) after reports of significant adverse liver reactions in trial subjects. The first cohort experienced multiple alanine aminotransferase (ALT) flares, leading to a hospitalization. Despite this setback, Aligos plans to focus on advancing other clinical programs, including ALG-000184 and ALG-055009. With a financial strategy in place, the company expects to sustain operations into the first half of 2024 while pursuing innovative therapies for viral and liver diseases.

Aligos Therapeutics (ALGS) reported a net loss of $128.3 million for 2021, with cash and investments totaling $205.8 million as of December 31, 2021, enough to fund operations into H1 2024. The company advanced multiple drug candidates in CHB, NASH, and COVID-19, with significant milestones expected throughout 2022. Collaboration with Merck on NASH has expanded, highlighting Aligos' oligonucleotide technology. Research and development expenses increased to $104.2 million, driven by ongoing clinical activities and staffing costs.